EarningsQ3 2026 Earnings Report
MX:EMBC Q3 2026 EPS Results
Actual EPS$9.53
Consensus EPS$4.53
Beat/MissBeat by +$5.00
One Year Ago EPS$19.07
MX:EMBC Q3 2026 Revenue Results
Actual Revenue$4.63B
Expected Revenue$4.33B
Beat/MissBeat by +$292.36M
YoY Revenue Growth-8.05%
Earnings Announcement Details
QuarterQ3 2026
Date08/07/2026
TimeBefore Open
Conference CallFriday, August 7, 2026
MX:EMBC Upcoming Earnings
Embecta Corporation's next earnings date is estimated for December 1, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:EMBC Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: significant strategic progress (Owen Mumford acquisition expanding TAM, international growth, sequential operational improvement, margin/earnings guidance upgrades, brand transition and organizational reinforcements) offset by sizable year‑over‑year declines in U.S. revenue, gross profit and operating profit, pen needle headwinds, and macro volume pressures. Management emphasized execution, cost controls, and deleveraging while reaffirming revenue guidance and raising margin and EPS targets, resulting in cautious optimism but clear near‑term financial challenges.Company Guidance
Owen Mumford Acquisition and Strategic Expansion
Closed acquisition of Owen Mumford on May 15; integration progressing as planned. Expands product portfolio beyond insulin devices into pharmaceutical services and auto-injectors (Aidaptus). Management estimates total addressable auto-injector market ≈ $2.4B with double-digit CAGR. Added 4 sites (3 manufacturing: 2 UK, 1 Malaysia; 1 U.S. warehouse) to broaden manufacturing/distribution footprint.
Sequential Improvement in Q3 Performance
Sequential vs Q2: total revenue improved by approximately $50M; GAAP operating income improved ≈ $14M; adjusted operating income improved ≈ $21M. Q3 adjusted gross profit improved ≈ $26M sequentially, driven by improved U.S. and International performance and initial Owen Mumford contribution.
International Strength
International revenue in Q3 ≈ $151M, up 11.5% reported and up 9.7% on an adjusted constant currency basis, driven by Latin America and Asia and contribution from Owen Mumford.
Margin and EPS Guidance Upside
Raised adjusted operating margin guidance from 22.25-23.25% to 23.5-24.0%. Raised adjusted EPS guidance from $1.55-1.75 to $1.80-1.90, driven by operating expense controls and cost optimization initiatives.
Cash Generation and Deleveraging Progress
Generated approximately $41M in free cash flow in Q3. Repaid ~ $53M of debt in the quarter and ~ $128M through first 9 months of 2026; expect to repay at least $150M in 2026. Last-12-month net leverage ≈ 3.7x (below covenant requirement of 4.75x). Amended and extended revolving credit facility through December 30, 2028.
Brand Transition and Commercial Wins
Completed brand transition in key European, Asian, and Latin American markets; >90% of revenue now under the Embecta label and on track to substantially complete global brand transition by end of calendar 2026. Expanded B2B co-packaging momentum with generic GLP-1 launches (Canada, Brazil, South Africa, India) and small-pack launches planned/in-market.
Leadership and Organizational Moves
Appointed Jeff Mann as President of Pharma Services and Product Management and Chief Legal Officer to lead pharma services organization; hired Nimish Muzumdar as SVP and President, North America to strengthen commercial execution.
MX:EMBC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed